UC or Crohn’s – TV48574-IMM-20036

A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)

Register Today!

Trial Information

Start DateSummer 2023
End DateTBD
Trial Duration18 weeks
Number of Visits10
StatusIn Start-up

For additional information
on this trial contact: